Table 1.
Characteristics of the ROADMAP‐OFU Patient Population at OFU Baseline (=Final ROADMAP Visit)
| ROADMAP‐OFU Baseline/Final ROADMAP Visit | |||
|---|---|---|---|
| Placebo (n=877) | Olmesartan (n=881) | P Value | |
| Male gender, n (%) | 418 (47.7) | 441 (50.1) | 0.3153 |
| Age, y | 61.3 (8.4) | 61.2 (8.5) | 0.8234 |
| Roadmap duration (y), mean (SD) | 3.3 (0.6) | 3.4 (0.6) | 0.6908 |
| Body mass index (kg/m2), mean (SD) | 30.7 (4.9) | 31.0 (4.8) | 0.1776 |
| Duration of diabetes (y), mean (SD) | 9.7 (5.9) | 9.7 (6.0) | 0.9185 |
| Blood glucose (mmol/L), mean (SD) | 9.6 (3.4) | 9.3 (3.2) | 0.0779 |
| HbA1c (%), mean (SD) | 7.8 (1.6) | 7.7 (1.6) | 0.0896 |
| Average number of antihypertensive drugs*, (SD) during ROADMAP | 2.3 (1.5) | 2.1 (1.5) | 0.0005 |
| SBP (mm Hg), mean (SD) | 127.5 (11.0) | 124.2 (10.7) | <0.0001 |
| DBP (mm Hg), mean (SD) | 74.5 (7.5) | 72.5 (8.1) | <0.0001 |
| eGFR (mL/min), mean (SD) | 81.8 (17.5) | 78.1 (18.0) | <0.0001 |
| Total cholesterol (mmol/L), mean (SD) | 5.1 (1.2) | 5.1 (1.4) | 0.4813 |
| HDL (mmol/L), mean (SD) | 1.3 (0.4) | 1.3 (0.4) | 0.1265 |
| LDL (mmol/L), mean (SD) | 2.9 (1.0) | 2.9 (1.0) | 0.8846 |
| Triglyceride (mmol/L), mean (SD) | 2.1 (1.6) | 2.2 (2.9) | 0.1433 |
| At baseline of ROADMAP main study | |||
| Smoker, n (%) | 139 (15.8) | 139 (15.8) | 0.9670 |
| History of coronary heart disease, n (%) | 183 (20.9) | 198 (22.5) | 0.4133 |
DBP indicates diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; OFU, observational follow up; ROADMAP, Randomized Olmesartan and Diabetes Microalbuminuria Prevention; SBP, systolic blood pressure.
*
With exception of olmesartan.